Cue Biopharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 13.11 million compared to USD 14.26 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.44 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9402 USD | -0.85% |
|
-2.06% | -64.39% |
Jul. 01 | Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 3000E Growth Index | CI |
Jul. 01 | Cue Biopharma, Inc.(NasdaqCM:CUE) dropped from Russell 2000 Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.39% | 45.73M | |
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- CUE Stock
- News Cue Biopharma, Inc.
- Cue Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023